scroll to top.svgleft arrow.svgright arrow-1.svg
AAAAI logo.svg
share_on_x_twitter.svgShare on Facebook.svgshare on Linkedin.svg

Board of Directors June Meeting Highlights

The AAAAI Board of Directors met in person June 17-19, 2022, in Chicago, Illinois. The members of the Board of Directors appreciate the work of AAAAI committee members and chairs as they strive toward the AAAAI mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care. Over the course of the meeting, a number of significant decisions and actions were made. Here are the highlights:
A number of requests were granted approval, including updates to the Members Only section of the AAAAI website and funding for the 2023 MIPS reporting module in the AAAAI Quality Clinical Data Registry, as well as the 2023 Leadership Institute. Funding for the 2023 Winter Meeting for the Program Directors Assembly and Academic Leaders was approved along with travel funds for the In-Training Examination Committee to attend the meeting. The Board also approved the dissolution of the Office of School-based Management of Asthma and Allergies and creation of the SA3MPRO Committee under the HETQ Interest Section.
Multiple awards were discussed and approved, including the 2023 Honorary Awards and the new Lifetime Contribution to the AAAAI and A/I Specialty Award. Additionally on the AAAAI Foundation side, approval was granted to present up to four Faculty Development Awards in 2023.
Presidential Presentations
David A. Khan, MD, FAAAAI, shared more on his presidential initiatives and updates.
  • Drug Hypersensitivity Research Award: Approval of $150,000 in funding for one to three awardees for the AAAAI Drug Hypersensitivity Research Grant for the 2023 award cycle.
  • Prior Authorization Task Force: Creation of three subgroups including:
    1. Advocacy to review Congressional and state legislation already passed and pending
    2. Proposing and developing an AAAAI position statement on prior authorization
    3. Developing a work group report on the impact of prior authorizations on A/I care.
  • Regional Outreach on Allergy/Immunology for Residents (ROAR): Funding approval for three regional sessions of the ROAR program to be held in Washington, DC, Chicago, Illinois, and San Diego, California.
The Board also spent time during this meeting discussing the value proposition of the AAAAI. Words that resonated with the Board included transformative, leadership, advocacy, education, partnership and connection. They will continue to develop this proposition in the coming months. Board members also discussed the National Allergy Bureau™ and steps to continue to move this initiative forward.
A number of other projects and topics were discussed, including a newly proposed licensing policy for AAAAI materials and funding for a medical copy editor to review the Practice Management Resource Guide.
In addition, the three divisions of the Board of Directors—Education, Practice & Policy and Research & Training—met individually to discuss committee activities.
The next Board of Directors meeting
November 18-20, 2022
Washington, DC